EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> The FDA cleared BioLineRx to trial anti-cancer vaccine AGI-134 in solid tumors. The action sets BioLineRx up to expand the trial beyond the U.K. and Israel by opening sites in the U.S. in the first half of next year. Release 

> eTheRNA immunotherapies opened a new research base in Ghent, Belgium. The site will house the biotech’s enlarged research and preclinical teams. Statement 

> Sylentis presented new data from its failed phase 3 dry eye disease trial. The analysis linked siRNA drug tivanisiran to statistically significant improvements in patients with Sjögren's syndrome. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> BerGenBio completed enrollment into the second stage of a phase 2 lung cancer trial that is testing AXL inhibitor bemcentinib in combination with Merck’s Keytruda. Statement 

> OMass Therapeutics appointed Rosamond Deegan as CEO. Deegan joins OMass from Bicycle Therapeutics, where she served as chief business officer. Release 

Suggested Articles

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.

The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B.